U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.
Robin Ghertner
https://pubmed.ncbi.nlm.nih.gov/31525570Actively Recruiting
Led by University of Maryland, College Park · Updated on 2026-04-27
160
Participants Needed
4
Research Sites
8 weeks
Total Duration
U
University of Maryland, College Park
Lead Sponsor
U
University of Maryland, Baltimore
Collaborating Sponsor
This research aims to evaluate a peer-led, brief behavioral intervention designed to improve medication adherence for opioid use disorder (MOUD) and reduce polysubstance use among patients with opioid use disorder (OUD) and polysubstance use in underserved areas. The study focuses on a behavioral activation (BA) approach delivered by trained peer recovery specialists (PRSs) and compares it to treatment as usual (TAU) over a 12-month period. The trial addresses challenges in OUD treatment retention, especially in communities with limited access to addiction care and rising stimulant use. Participants will be randomly assigned to either the Peer Activate intervention or enhanced treatment as usual. Those in the Peer Activate group will receive about six weekly core sessions, lasting 30 minutes to one hour, led by PRSs teaching behavioral activation and problem-solving skills. Additionally, up to six optional booster sessions are available to reinforce these skills. The TAU group receives standard telemedicine services enhanced with community referrals and follow-ups, plus regular meetings with addiction medicine physicians and PRSs for general support. Throughout the study, participants will be monitored with urinalysis and self-reports to assess polysubstance use, treatment retention, and medication adherence over six months. Researchers will also track intervention attendance, uptake, and fidelity. The trial includes multiple assessments to measure problems related to substance use and the effectiveness of peer-delivered behavioral activation in improving outcomes for patients receiving telemedicine buprenorphine treatment. Total participation and follow-up last at least 12 months.
CONDITIONS
Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Approximately 12 weeks
Participants receive peer-delivered behavioral activation sessions to support opioid use disorder treatment retention and reduce polysubstance use. This includes about six weekly core sessions and up to six optional booster sessions.
Weekly sessions for up to 12 weeks
Duration - Up to 6 months
Participants are followed for ongoing assessment of treatment retention, substance use, and adherence over six months after starting the intervention.
Regular assessments during the 6-month follow-up period
Total: 4 locations
1
HIPS Clinic
Washington D.C., District of Columbia, United States, 20002
Not Yet Recruiting
2
University of Maryland Baltimore (UMD Drug Treatment Center)
Baltimore, Maryland, United States, 21223
Not Yet Recruiting
3
University of Maryland, College Park
College Park, Maryland, United States, 20742
Not Yet Recruiting
4
Caroline County Behavioral Health
Denton, Maryland, United States, 21629
Actively Recruiting
M
Morgan S Anvari, BA
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Robin Ghertner
https://pubmed.ncbi.nlm.nih.gov/31525570Jessica F Magidson, Stephanie M Gorka, Laura MacPherson...
https://pubmed.ncbi.nlm.nih.gov/21310539Matthew J Mimiaga, Sari L Reisner, David W Pantalone...
https://pubmed.ncbi.nlm.nih.gov/23030605Matthew J Mimiaga, David W Pantalone, Katie B Biello...
https://pubmed.ncbi.nlm.nih.gov/30887824Stacey B Daughters, Jessica F Magidson, Deepika Anand...
https://pubmed.ncbi.nlm.nih.gov/28963853Jessica F Magidson, C J Seitz-Brown, Steven A Safren...
https://pubmed.ncbi.nlm.nih.gov/25419102Jessica F Magidson, John A Joska, Kristen S Regenauer...
https://pubmed.ncbi.nlm.nih.gov/31082664Stacey B Daughters, Jessica F Magidson, Randi M Schuster...
https://pubmed.ncbi.nlm.nih.gov/21709737Matthew T Tull, Christopher R Berghoff, Joseph R Bardeen...
https://pubmed.ncbi.nlm.nih.gov/28799413Kathleen M Carroll
https://pubmed.ncbi.nlm.nih.gov/25204847